# reload+after+2024-01-20 07:43:58.929753
address1§170 Park Avenue
city§Florham Park
state§NJ
zip§07932
country§United States
phone§908 768 2170
website§https://www.celularity.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
fullTimeEmployees§225
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Robert Joseph Hariri M.D., Ph.D.', 'age': 64, 'title': 'Founder, CEO & Chairman (Leave of Absence)', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 1242521, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David C. Beers C.F.A.', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 455021, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John R. Haines', 'age': 65, 'title': 'Senior EVP, Global Manager & Chief Administrative Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 503563, 'exercisedValue': 0, 'unexercisedValue': 103633}, {'maxAge': 1, 'name': 'Ramji  Krishnan', 'title': 'Chief Technology Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Carlos  Ramirez', 'title': 'SVP of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kyle Harold Fletcher Esq.', 'age': 38, 'title': 'Executive VP, General Counsel & Chief Compliance Officer', 'yearBorn': 1985, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stephen A. Brigido D.P.M.', 'age': 47, 'title': 'President of Degenerative Diseases', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Adrian  Kilcoyne M.B.A., M.D., M.P.H.', 'age': 52, 'title': 'Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Sharmila  Koppisetti M.D.', 'title': 'Senior Vice President of Clinical Dev. Immunology & Drug Safety', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tim  Wilk', 'title': 'Senior Vice President of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§10
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.232
priceToSalesTrailing12Months§3.2117913
currency§USD
dateShortInterest§1702598400
forwardEps§-0.57
exchange§NCM
quoteType§EQUITY
shortName§Celularity Inc.
longName§Celularity Inc.
firstTradeDateEpochUtc§1565271000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§acab037e-115e-3a22-b200-e5ce523f37ff
gmtOffSetMilliseconds§-18000000
targetHighPrice§2.5
targetLowPrice§2.5
targetMeanPrice§2.5
targetMedianPrice§2.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§0.052
grossMargins§0.21193
ebitdaMargins§0.0
trailingPegRatio§None
